6th May 2021
- 0 comments
Mogrify Limited, a biopharmaceutical company aiming to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies, has completed the second closing of its Series A financing of $17 million USD, bringing the total raised to $33 million USD in this round.
...Register / Login now to read full story
In order to read the full story we need you to be registered with us, please click the links below to login or register.
Back to Homepage